PATENT CLAIM ANALYSIS

Application Number: 15884608
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-08
Patent Classification: ["424", "093210"]

Abstract:
The presently disclosed subject matter provides for methods and compositions for treating cancer (e.g., multiple myeloma). It relates to anti-CD56 antibodies, chimeric antigen receptors (CARs) that specifically target human CD56, and immunoresponsive cells comprising such CARs. The presently disclosed CD56-specific CARs have enhanced immune-activating properties, including anti-tumor activity.

Claim (Index 10):
The CAR of  claim 4 , wherein the extracellular antigen-binding domain comprises:\n a heavy chain variable region comprising an amino acid sequence that is at least 80% homologous to SEQ ID NO:7; and/or a light chain variable region comprising an amino acid sequence that is at least 80% homologous to SEQ ID NO:8.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 86.0
- Lexical Diversity: 1.31111
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15368278', '15613800', '14805193', '14805075', '15511973']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7785625449185368
- 35 USC 102 Novelty (BERT): 0.5778425067906051
- Combined Prediction Score: 0.7584905411057437
- Mean Citation Score: 480.936978
- Max Citation Score: 561.69855
- Similarity Product: 377.75684664166863

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test